Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

The stock's fall snapped a three-day winning streak.

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...